Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Separate transcription and splicing gene networks are linked and coordinated by the pRb-E2F pathway.

Nucleic acids research·2026
Same author

Brain capillary endothelial-like cells show altered barrier functionality and reduced transport of amyloid β in late-onset Alzheimer disease.

Fluids and barriers of the CNS·2026
Same author

Mutant huntingtin impairs neurodevelopment in human brain organoids through CHCHD2-mediated neurometabolic failure.

Nature communications·2024
Same author

Citrullination and the protein code: crosstalk between post-translational modifications in cancer.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2023
Same author

Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response.

Nature communications·2023
Same author

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity.

Communications biology·2023

Related Experiment Video

Updated: May 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

HDAC inhibitor-based therapies: can we interpret the code?

Maria New1, Heidi Olzscha, Nicholas B La Thangue

  • 1Department of Oncology, Laboratory of Cancer Biology, University of Oxford, Oxford OX3 7DQ, UK.

Molecular Oncology
|November 13, 2012
PubMed
Summary

Histone deacetylase inhibitors (HDIs) show promise in cancer therapy by targeting abnormal epigenetic control. Further research is needed to understand their mechanisms and expand their use beyond cutaneous T-cell lymphoma.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Related Experiment Videos

Last Updated: May 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Pharmacology

Background:

  • Abnormal epigenetic regulation, particularly aberrant acetylation, is an early event in tumor progression.
  • Histone deacetylases (HDACs) play a crucial role in regulating gene expression by controlling histone and non-histone protein acetylation.
  • Histone deacetylase inhibitors (HDIs) are emerging as a promising therapeutic strategy for various cancers.

Purpose of the Study:

  • To explore the therapeutic potential of histone deacetylase inhibitors (HDIs) in cancer treatment.
  • To elucidate the mechanisms by which HDIs exert their anti-tumor effects.
  • To identify potential new applications for HDI-based therapies beyond cutaneous T-cell lymphoma (CTCL).

Main Methods:

  • Review of existing literature on HDACs, HDIs, and their role in cancer.
  • Analysis of cell-based studies investigating the outcomes of HDI treatment.
  • Examination of approved and clinical trial HDI-based therapies.

Main Results:

  • HDIs are potent anti-proliferative agents that induce apoptosis, cell-cycle arrest, differentiation, anti-angiogenesis, and autophagy in tumor cells.
  • Vorinostat (SAHA) and romidepsin (FK228) are approved for CTCL treatment, with others in clinical trials.
  • The precise pathways through which HDIs impact tumor growth are not fully understood.

Conclusions:

  • HDIs represent a significant advancement in epigenetic cancer therapy.
  • A deeper understanding of HDI mechanisms is crucial for expanding their clinical utility to other malignancies.
  • Further research is warranted to optimize HDI-based treatment strategies and identify responsive tumor types.